Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 6Solid Tumor 3Neoplasms 3Advanced Solid Tumors 3Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Solid Tumor 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Squamous NSCLC 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Melanoma 1MSI-H 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gastrointestinal Diseases 1Esophageal Diseases 1Carcinoma, Squamous Cell 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumours 1

Interventions

sintilimab 1Paclitaxel 1Ocoxin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Diseases × sintilimab × Clear all
NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡